A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Status: Recruiting
Phase: Phase 1
Diagnosis: Lung Cancer
NCT ID: NCT01283516 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-452

 

This study will assess the safety and efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK)

 

Conducting Institutions:
Massachusetts General Hospital, Dana-Farber Cancer Institute

Overall PI:
Alice Shaw, MD, PhD, Massachusetts General Hospital

Site-responsible Investigators:
Pasi Janne, MD, PhD, Dana-Farber Cancer Institute

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Kelly Masone, 617-632-3383, kmasone@partners.org

Eligibility Criteria

Inclusion Criteria: • Tumor must be confirmed to be ALK positive Exclusion Criteria: - Pregnant - Active pancreatitis - Active or chronic liver disease Other protocol-defined inclusion/exclusion criteria may apply
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms